CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced that it will present four scientific ...

Cognito Therapeutics has delivered clinical data from its digital treatment for patients with Alzheimer’s disease—which relies on light and sound to stimulate specific electrical frequencies in the ...

Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...

Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation ...

强化学习已被证明能够有效提升大型语言模型（LLM）的推理能力。最近的研究工作逐步将这一范式扩展到多模态推理任务。由于多模态任务在语义内容与问题形式上的固有复杂性与多样性，现有模型在跨领域和不同难度级别的问题上表现不够稳定。 针对上述挑战 ...

HOPE is evaluating Cognito’s investigative non-invasive neuroprotective therapy to better preserve cognition and function in patients with Alzheimer’s. The study is the largest ever medical device ...

Cogito, a real-time feedback platform for customer service agents, added $15 million to its coffers today in the form of a Series B. This brings the company’s total fundraising to $22.5 million. The ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying ...

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline. Cognito, based in Cambridge, Mass., is developing a headset that ...